GLP1R and Hepatic fibrosis: In addition, at least in the pre-clinical stage, a dual glucagon-like peptide-1 receptor/glucagon receptor (GLP-1R/GCGR) agonist inhibited liver fibrosis via blocking the activation of the pro-inflammatory nuclear factor kappa B/NF-kappa-B inhibitor alpha (NFκB/IKBα) signaling pathway, as well as the c-Jun N-terminal kinase (JNK)-dependent initiation of hepatocyte death.